ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Drug Costs in Federally Sponsored Cancer Clinical Trials: A Systematic Review.JAMA network open · 2026Pooled it
- Geographic access to triple negative breast cancer clinical trials: are trials located near patients?Breast cancer research and treatment · 2026Article
- A Standardized Screening and Prioritization Tool in Support of Program-Based Quality Improvement.Annals of surgical oncology · 2026Article
- Ensuring the Future of Cooperative Group Cancer Clinical Trials: A Call for Comprehensive Support and Prioritization.JCO oncology practice · 2026Article
- Real-world evaluation of user engagement with an artificial intelligence-powered clinical trial application in oncology.Journal of the American Medical Informatics Association : JAMIA · 2025Article
- Not all trials are created equal: the unique role of the NCI National Clinical Trials Network.Journal of the National Cancer Institute · 2025Article
- Determinants of first-line clinical trial enrollment among Black and White gynecologic cancer patients.Cancer causes & control : CCC · 2025Observational
- When to adjust for multiplicity in cancer clinical trials.Journal of the National Cancer Institute. Monographs · 2025Article
- Accelerating progress to reduce the cancer burden through prevention and control in the United States.Journal of the National Cancer Institute · 2025Article
- Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response.Nature reviews. Clinical oncology · 2024Review
- Patient Enrollment to Industry-Sponsored Versus Federally-Sponsored Cancer Clinical Trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Correlative Science in the Cooperative Group System: Re-Engineering for Success.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Decentralized Clinical Trials in Early Drug Development-A Framework Proposal.Journal of immunotherapy and precision oncology · 2024Review
- The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership.Journal of the National Cancer Institute · 2023Article
- Organization of Cancer Specialists in US Physician Practices and Health Systems.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Cancer statistics, 2026: Charting a course for a national cancer research agenda.CA: a cancer journal for cliniciansArticle
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
14 authors at 10 institutions in 1 country.
Funding
Abstract
purposeIn the United States, the National Cancer Institute National Cancer Clinical Trials Network (NCTN) groups have conducted publicly funded oncology research for 50 years. The combined impact of all adult network group trials has never been systematically examined.
methodsWe identified randomized, phase III trials from the adult NCTN groups, reported from 1980 onward, with statistically significant findings for ≥ 1 clinical, time-dependent outcomes. In the subset of trials in which the experimental arm improved overall survival, gains in population life-years were estimated by deriving trial-specific hazard functions and hazard ratios to estimate the experimental treatment benefit and then mapping this trial-level benefit onto the US cancer population using registry and life-table data. Scientific impact was based on citation data from Google Scholar. Federal investment costs per life-year gained were estimated. The results were derived through December 31, 2020.
resultsOne hundred sixty-two trials comprised of 108,334 patients were analyzed, representing 29.8% (162/544) of trials conducted. The most common cancers included breast (34), gynecologic (28), and lung (14). The trials were cited 165,336 times (mean, 62.2 citations/trial/year); 87.7% of trials were cited in cancer care guidelines in favor of the recommended treatment. These studies were estimated to have generated 14.2 million (95% CI, 11.5 to 16.5 million) additional life-years to patients with cancer, with projected gains of 24.1 million (95% CI, 19.7 to 28.2 million) life-years by 2030. The federal investment cost per life-year gained through 2020 was $326 in US dollars.
conclusionNCTN randomized trials have been widely cited and are routinely included in clinical guidelines. Moreover, their conduct has predicted substantial improvements in overall survival in the United States for patients with oncologic disease, suggesting they have contributed meaningfully to this nation's health. These findings demonstrate the critical role of government-sponsored research in extending the lives of patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.